Journals / İzmir Atatürk Eğitim Hastanesi Tıp Dergisi / 2008 / Cilt: 46 - Sayı: 1

Comparison of the in-vitro activity of different quinolones to respiratory system pathogens

Farklı kinolonların solunum sistemi patojenlerine in-vitro etkinliğinin karşılaştırılması

Pages
9–14
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most active quinolone against gram negative bacillus was ciprofloxacin (76.2 %) and it was followed by moxifloxacin (71.5 %), levofloxacin (71.1 %), and ofloxacin (60.7 %).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:n this report, clinical samples of the patients with respiratory system infections were evaluated using bacteriologic culture methods.
📊
Key Findings & Data:Of the 150 pathogen bacteria that were included in the study 97 (64.7%) of them were gram negative bacilli and 53 (35.3 %) of them were gram positive cocci.
💡
Conclusion & Impact:The most active quinolone against gram negative bacillus was ciprofloxacin (76.2 %) and it was followed by moxifloxacin (71.5 %), levofloxacin (71.1 %), and ofloxacin (60.7 %).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

n this report, clinical samples of the patients with respiratory system infections were evaluated using bacteriologic culture methods. In-vitro susceptibility of the isolated bacteria to different quinolones were investigated and the results were compared. Of the 150 pathogen bacteria that were included in the study 97 (64.7%) of them were gram negative bacilli and 53 (35.3 %) of them were gram positive cocci. The most frequently isolated gram negative bacilli and gram positive bacteria cocci were Pseudomonas aeruginosa and methicilline sensitive Staphylococcus aureus (MSSA) respectively. When in-vitro activity of the quinolones were compared, the most active one against gram positive cocci was moxifloxacin (98.2 %) and it was followed by levofloxacin (95.2 %), ciprofloxacin (78 %), and ofloxacin (77.6 %). The most active quinolone against gram negative bacillus was ciprofloxacin (76.2 %) and it was followed by moxifloxacin (71.5 %), levofloxacin (71.1 %), and ofloxacin (60.7 %).

Özet

Bu çalışmada, solunum yolu infeksiyonu tanılı hastalardan alınan klinik örnekler bakteriyolojik kültür yöntemi ile incelendi. İzole edilen bakterilerin farklı kinolonlara duyarlılıkları in-vitro olarak incelendi ve sonuçlar karşılaştı-rıldı. Çalışmaya alınan 150 adet patojen bakteriden 97 (%64.7)’si gram olumsuz basil, 53 (%35.3)’ü gram olumlu kok idi. En sık izole edilen gram olumsuz basil ve gram olumlu kok sırası ile Pseudomonas aeruginosa ve metisilin duyarlı Staphylococcus aureus (MSSA) idi. Kinolonların in-vitro etkinlikleri karşılaştırıl-dığında gram olumlu koklara en etkin moksifloksasin (%98.2) idi. Bunu sırasıyla levofloksasin (%95.2), siprofloksasin (%78) ve ofloksasin (%77.6) izlemekte idi. Gram olumsuz basillere en etkin siprofloksasin (%76.2) idi. Bunu sırasıyla moksifloksasin (%71.5), levofloksasin (%71.1) ve ofloksasin (%60.7) izlemekte idi.

🔖

Cite This Article

COŞKUN, N. A., TÜRKER, M., YAVAŞ, S. Y., TÜRKER, N., EL, S., URAL, S., VARDAR, İ., ÖRMEN, B., KAPTAN, F. (2022). Comparison of the in-vitro activity of different quinolones to respiratory system pathogens. İzmir Atatürk Eğitim Hastanesi Tıp Dergisi, Cilt: 46 - Sayı: 1, 9–14. https://ajindex.com/articles/557540

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Duma R. Pneumococcal Pneumoniae. In: Goldman L, Bennett JC. Eds. Cecil Textbook of Medicine. Philadephia: WB Saunders, 2000: 1603-1609
  2. Marrie TJ. Community-Acquired Pneumonia: Epidemiology, Etiology, Treatment. Inf Dis Clin N Amer 1998; 12: 723-739
  3. Ball P. Quinolone generations: natural history or natural selection. J Antimicrob Chemother 2000; 46: 17
  4. Hooper DC. Quinolones. In: Mandell GL, Bennett JE, Dolin R. Eds. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000: 404
  5. Hooper DC. New uses for new and old quinolones and challenge of resistance. Clin Infect Dis 2000; 30: 243
  6. NationalCommittee for ClinicalLaboratory Disk Susceptibility tests. Aproved Standarts M2-A6 Wayne, PA: NNCCSA, 1997
  7. Eliopoulas GM. Invitro activity of floroquinolones against gram-positive bacteria. Drugs 1995; 49: 48-57
  8. Goldstein FW.Acor JF. Epidemiology of quinolone resistance: Europe North and South America. Drugs 1995; 49: 36-42
  9. Piddock LJV. Flouroquinolone resistance. BMJ 1998; 317: 1029-30
  10. Marchese A, Baca D, Balistreti G. et al. Activity of moxifloxacin (BAY 12-8039) against erythromycin-resistant streptococcus pyogenes. Antiinfect Drug Chemother 1998; 42: 1868
  11. Blondeau JM. A review of the comperative in vitro activities of 12 antimicrobial agents with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999; 43: 1-11
  12. Isaacson DM, Fernandez JA, Fracom et al. Levofloksasin: a review of its antibacterial activity. Recent Res Pevel Antimicrobial Chemother 1996; 1: 301-439
  13. Davis R, Bryan HM. Levofloxacin a review of its antibacterial activity, pharmacokinetics and theropeutic efficiacy. Drugs 1994; 47: 677-700
  14. Goofz TD, McGuırk PR. New quınolones in development. Expert Opin İnvest Drugs (UK) 1994; 3: 93-114
  15. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic proporties of BAY 12-8039 on gram pozitive and gram negative organismis as demonstrated by studies of time-kill kinetics and post antiobiotic effects. Antimicrob Agents Chemother 1999; 43: 13-8
  16. Rouse MS, Piper KE, Patel R et al. İnvitro and invivo activity of ciprofloxacin, levofloxacin, sperfoxacin or BAY 12-8039 against penicilin-resistant streptococcus pneomoniae. 37 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1997; Toronto, Canada: B-3 17. Kligman KP, Cooper T. Concentration-dependent killing of antiobiotic-resistant pneumococus by the methoxyquınolone moxifloxacin. J Antimicr